Please login to the form below

Not currently logged in
Email:
Password:

Abilify Maintena

This page shows the latest Abilify Maintena news and features for those working in and with pharma, biotech and healthcare.

Lundbeck’s key products shine in Q2 but problems remain

Lundbeck’s key products shine in Q2 but problems remain

Sales of Rexulti (brexpiprazole), Abilify Maintena (aripiprazole), Trintellix (vortioxetine) and Northera (droxidopa) increased by 20% to 44% in the quarter, resulting in overall sales of those key products coming in above

Latest news

  • Indivior push to diversify boosted by schizophrenia drug approval Indivior push to diversify boosted by schizophrenia drug approval

    Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna. ... It will launch in competition to other monthly therapies, such as Lundbeck/Otsuka’s market leading Abilify Maintena (aripiprazole) and Johnson

  • Lundbeck and Otsuka start phase III for Rexulti in bipolar Lundbeck and Otsuka start phase III for Rexulti in bipolar

    off the patent cliff in recent years and seen steep sales decline as a result, although a long-acting depot formulation (Abilify Maintena) is still making gains. ... Abilify. Lundbeck and Otsuka are also evaluating the drug in a phase II trial involving

  • Otsuka refiles 'digital' medicine for mental illness Otsuka refiles 'digital' medicine for mental illness

    The so-called 'digital medicine' consists of Otsuka's Abilify (aripiprazole) embedded with Proteus' ingestible sensor that is the size of a grain of sand, which records medication ingestion. ... The company's long-acting formulation Abilify Maintena is

  • Surging sales of Lundbeck's CNS drugs assist recovery Surging sales of Lundbeck's CNS drugs assist recovery

    Schizophrenia depot Abilify Maintena (aripiprazole) was up 78% to DKK 279m, and new drug for high blood pressure associated with Parkinson's disease - Northera (droxidopa) - romped away with a 136% rise ... Schultz said he was pleased with the sales

  • Allergan and Gedeon finally get antipsychotic green light Allergan and Gedeon finally get antipsychotic green light

    Once-monthly examples include Otsuka/Lundbeck's Abilify Maintena (aripiprazole) and Johnson and Johnson's Invega Sustenna (paliperidone palmitate), while J&J is also developing a three-monthly paliperidone depot that

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    At the end of February, the FDA approved Abilify Maintena (aripiprazole), an intramuscular extended-release depot formulation for the treatment of schizophrenia and the first commercialised product to evolve from this ... injectable in 14 European

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...